Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
Conference Call & Webcast
Thursday, August 7 @ 4:30 p.m. ET
Domestic:
1 833-470-1428
International:
1 404-975-4839
Access Code:
899803
Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call.
The webcast will be archived on the Investor Relations section of www.crinetics.com.
About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Investors:Gayathri DiwakarHead of Investor Relationsgdiwakar@crinetics.com (858) 345-6340
Media: Natalie BadilloHead of Corporate Communications nbadillo@crinetics.com (858) 345-6075
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Bruker, Viatris, Sotera Health Company, Align Technology, and Omnicell Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Research Tools & Consumables company Bruker (NASDAQ:BRKR) jumped 3.7%. Is now the time to buy Bruker? Access our full analysis report here, it's free. Generic Pharmaceuticals company Viatris (NASDAQ:VTRS) jumped 3.1%. Is now the time to buy Viatris? Access our full analysis report here, it's free. Research Tools & Consumables company Sotera Health Company (NASDAQ:SHC) jumped 3.1%. Is now the time to buy Sotera Health Company? Access our full analysis report here, it's free. Dental Equipment & Technology company Align Technology (NASDAQ:ALGN) jumped 3.3%. Is now the time to buy Align Technology? Access our full analysis report here, it's free. Healthcare Technology for Providers company Omnicell (NASDAQ:OMCL) jumped 3.1%. Is now the time to buy Omnicell? Access our full analysis report here, it's free. Zooming In On Bruker (BRKR) Bruker's shares are very volatile and have had 20 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 8 days ago when the stock dropped 7.4% on the news that the company reported disappointing second-quarter results and lowered its full-year financial forecast, citing challenging market demand. The company's revenue for the quarter landed at $797.4 million, which missed analyst expectations. A key metric, organic revenue, which measures sales growth from a company's core operations, fell by 7.0%. Earnings per share (EPS), a measure of profitability, came in at $0.32, significantly below the consensus estimate of $0.42. In response to the weak performance, Bruker cut its full-year guidance, and now projected an organic revenue decline between 2% and 4%. Management pointed to decreased demand for life-science research instruments, especially from U.S. academic and biopharma customers, as the primary cause. The company also announced a cost-saving plan intended to reduce annual expenses. Bruker is down 45.9% since the beginning of the year, and at $31.80 per share, it is trading 55% below its 52-week high of $70.67 from September 2024. Investors who bought $1,000 worth of Bruker's shares 5 years ago would now be looking at an investment worth $723.25. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
Yahoo
24 minutes ago
- Yahoo
Former Amazon aggregator turns to Solana, records $70K in daily rewards
Former Amazon aggregator turns to Solana, records $70K in daily rewards originally appeared on TheStreet. Despite Bitcoin's towering $113.3 billion in corporate treasuries versus just $3.44 billion for Solana, one Nasdaq-listed company is betting big on the smaller chain — and collecting daily rewards while doing it. Upexi (NASDAQ: UPXI), once an Amazon brand aggregator, has pivoted into crypto and become one of the first publicly traded firms to build a Solana-focused treasury. Speaking with Scott Melker, host of TheStreet Roundtable, Upexi CEO Alan Marshall said the move wasn't about following the herd into Bitcoin — it was about finding faster growth potential. 'I didn't want to be just another of the 50 Bitcoin treasury companies,' Marshall said. 'Love Bitcoin, but it's a $2.5 trillion asset. The fifth-largest asset would take immense, sovereign buying for Bitcoin to 5x from here. Solana is 4% of the size of Bitcoin and literally could dramatically increase this year and over the next couple of years.'Part of the attraction is Solana's thriving decentralized ecosystem. A dApp (decentralized application) is software that runs on a blockchain instead of a single company's server — think financial apps, marketplaces, or games where no one entity can change the rules. Solana consistently ranks at the top in daily active users, DApp revenue, and decentralized exchange (DEX) trading volumes, signaling a busy, growing network. For treasury holders like Upexi, Solana also offers an 8.1% staking yield — a way to earn passive income by helping secure the network. In simple terms, staking means locking up your SOL tokens so they can be used by validators (the blockchain's record-keepers) to process transactions. In return, stakers get rewards paid out in SOL. Marshall said: 'We announced a couple of days ago we're over 2 million Solana and our staking revenue is like $70,000 a day. If it was Bitcoin, it would be almost zero a day.' Before crypto, Upexi had built a $100 million run-rate business in Amazon brand aggregation. But pandemic-era debt tightening and the challenges of Amazon's platform pushed Marshall to seek 'something more technology-based and changing quickly.' The turning point came, he said, 'once the administration changed and the SEC decided that the US was finally going to lead in crypto and not be behind.'For Marshall, Solana's smaller size, vibrant DeFi activity, and income potential from staking make it the better long-term play — even if Bitcoin still dominates corporate treasuries. 'If headwinds become tailwinds, that amount of buying would push Solana up multiples of where it could push Bitcoin,' he said. Launched in 2018, Upexi began as an Amazon brand aggregator, acquiring and scaling consumer products in health, wellness, and pet care. Over time, it built its own marketing, logistics, and fulfillment infrastructure to grow these brands across Amazon, Walmart, and direct-to-consumer channels. In 2024, the company pivoted toward digital assets. Former Amazon aggregator turns to Solana, records $70K in daily rewards first appeared on TheStreet on Aug 12, 2025 This story was originally reported by TheStreet on Aug 12, 2025, where it first appeared. Sign in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
Thermo Fisher, ICU Medical, CONMED, Pediatrix Medical Group, and IQVIA Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Research Tools & Consumables company Thermo Fisher (NYSE:TMO) jumped 3%. Is now the time to buy Thermo Fisher? Access our full analysis report here, it's free. Medical Devices & Supplies - Cardiology, Neurology, Vascular company ICU Medical (NASDAQ:ICUI) jumped 3.4%. Is now the time to buy ICU Medical? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Diversified company CONMED (NYSE:CNMD) jumped 3.1%. Is now the time to buy CONMED? Access our full analysis report here, it's free. Specialized Medical & Nursing Services company Pediatrix Medical Group (NYSE:MD) jumped 4.1%. Is now the time to buy Pediatrix Medical Group? Access our full analysis report here, it's free. Drug Development Inputs & Services company IQVIA (NYSE:IQV) jumped 3%. Is now the time to buy IQVIA? Access our full analysis report here, it's free. Zooming In On Pediatrix Medical Group (MD) Pediatrix Medical Group's shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 4 months ago when the stock dropped 6.7% on the news that President Trump announced "reciprocal tariffs" on all US imports, set at a minimum rate of 10%. Markets reacted negatively to the announcement, reflecting deep concerns among investors about the broader economic implications. The tariffs were likely seen as a significant threat to global trade flows, with the potential to slow economic growth, drive up consumer prices, and spark retaliatory measures. Wedbush analyst Dan Ives captured the prevailing market anxiety, stating, "We would characterize this slate of tariffs as 'worse than the worst case scenario' the Street was fearing." His comment highlighted how the scope and severity of the tariffs far exceeded Wall Street's expectations, adding a new layer of uncertainty for businesses and investors. Pediatrix Medical Group is up 13.1% since the beginning of the year, but at $14.74 per share, it is still trading 14.5% below its 52-week high of $17.23 from February 2025. Investors who bought $1,000 worth of Pediatrix Medical Group's shares 5 years ago would now be looking at an investment worth $726.11. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
